The forgotten numbers: A closer look at COVID-19 non-fatal valuations.

Benefit-Cost Analysis CDC COVID-19 Pandemic VSI VSL Value of a Statistical Injury Value of a Statistical Life Willingness to Pay

Journal

Journal of risk and uncertainty
ISSN: 0895-5646
Titre abrégé: J Risk Uncertain
Pays: United States
ID NLM: 101087652

Informations de publication

Date de publication:
2020
Historique:
accepted: 21 10 2020
pubmed: 11 11 2020
medline: 11 11 2020
entrez: 10 11 2020
Statut: ppublish

Résumé

Our research estimates COVID-19 non-fatal economic losses in the U.S. using detailed data on cumulative cases and hospitalizations from January 22, 2020 to July 27, 2020, from the Centers for Disease Control and Prevention (CDC). As of July 27, 2020, the cumulative confirmed number of cases was about 4.2 million with almost 300,000 of them entailing hospitalizations. Due to data collection limitations the confirmed totals reported by the CDC undercount the actual number of cases and hospitalizations in the U.S. Using standard assumptions provided by the CDC, we estimate that as of July 27, 2020, the actual number of cumulative COVID-19 cases in the U.S. is about 47 million with almost 1 million involving hospitalizations. Applying value per statistical life (VSL) and relative severity/injury estimates from the Department of Transportation (DOT), we estimate an overall non-fatal unadjusted valuation of $2.2 trillion for the U.S. with a weighted average value of about $46,000 per case. This is almost 40% higher than the total valuation of $1.6 trillion (using about $11 million VSL from the DOT) for all approximately 147,000 COVID-19 fatalities. We also show a variety of estimates that adjust the non-fatal valuations by the dreaded and uncertainty aspect of COVID-19, age, income, and a factor related to fatality categorization. The adjustments show current overall non-fatal valuations ranging from about $1.5 trillion to about $9.6 trillion. Finally, we use CDC forecast data to estimate non-fatal valuations through November 2020, and find that the overall cumulative valuation increases from about $2.2 trillion to about $5.7 trillion or to about 30% of GDP. Because of the larger numbers of cases involved our calculations imply that non-fatal infections are as economically serious in the aggregate as ultimately fatal infections.

Identifiants

pubmed: 33169048
doi: 10.1007/s11166-020-09339-0
pii: 9339
pmc: PMC7609384
doi:

Types de publication

Journal Article

Langues

eng

Pagination

155-176

Informations de copyright

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020.

Références

JAMA Intern Med. 2020 Oct 1;180(10):1336-1344
pubmed: 32609310
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Health Econ. 2008 Jan;17(1):55-66
pubmed: 17405185
Health Econ. 2014 Apr;23(4):384-96
pubmed: 23520055
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Risk Anal. 2021 May;41(5):761-770
pubmed: 32677076
Science. 2020 Aug 14;369(6505):846-849
pubmed: 32576668
Health Econ. 2005 Jan;14(1):83-91
pubmed: 15386665
Risk Anal. 2011 Sep;31(9):1381-407
pubmed: 21957946
J Risk Uncertain. 2020;61(2):101-128
pubmed: 33162671
J Risk Uncertain. 2020;61(2):129-154
pubmed: 33199940

Auteurs

Thomas J Kniesner (TJ)

Claremont Graduate University, Syracuse University (Emeritus), IZA, Claremont, CA USA.

Ryan Sullivan (R)

Naval Postgraduate School, Monterey, CA USA.

Classifications MeSH